Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.
Shandong Xinhua Pharmaceutical Company Limited announced that all resolutions proposed at their Annual General Meeting (AGM) were approved. This includes the review and approval of the 2024 annual report, financial report, and profit distribution plan. Additionally, the reappointment of Grant Thornton Zhitong Certified Public Accountants LLP as the auditor for 2025 was confirmed. The AGM also approved the remuneration for directors and supervisors and proposed amendments to the Articles of Association. The successful passing of these resolutions signifies a stable operational outlook and continued strategic direction for the company, potentially reinforcing its position in the pharmaceutical market.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a joint stock company based in the People’s Republic of China, operating within the pharmaceutical industry. The company is primarily involved in the production and distribution of pharmaceutical products.
Average Trading Volume: 4,632,376
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.69B
Learn more about 0719 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue